Experimental CAR-T therapy for rare solid tumors stalls after single patient
NCT ID NCT07123493
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested a personalized cell therapy called anti-ALPP CAR-T cells in people with advanced solid tumors that have the ALPP protein. Only one participant was enrolled before the study was terminated. The main goal was to check safety and find the right dose, not to prove the treatment works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Anti-ALPP CAR-T cells
- What this could lead to
- If successful, this approach could point toward a new treatment option for certain hard-to-treat solid tumors that express ALPP.
- What could go wrong
- This was a very early, small trial (only 1 participant) that was terminated, so results are extremely limited. CAR-T cell therapy can cause severe side effects like cytokine release syndrome.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT OR METASTATIC SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing GoBroad Hospital
Beijing, Beijing Municipality, 102200, China